{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:37:52Z","timestamp":1784565472221,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health, National Heart, Lung and Blood Institute","award":["HL128996"],"award-info":[{"award-number":["HL128996"]}]},{"name":"National Institutes of Health, National Heart, Lung and Blood Institute","award":["HL113039"],"award-info":[{"award-number":["HL113039"]}]},{"name":"National Institutes of Health, National Heart, Lung and Blood Institute","award":["HL116263"],"award-info":[{"award-number":["HL116263"]}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["CSA2066001"],"award-info":[{"award-number":["CSA2066001"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["POST26630003"],"award-info":[{"award-number":["POST26630003"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.pharmthera.2016.09.001","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T23:24:14Z","timestamp":1473463454000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["HDL and microRNA therapeutics in cardiovascular disease"],"prefix":"10.1016","volume":"168","author":[{"given":"Danielle L.","family":"Michell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey C.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.09.001_bb0005","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0015","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/emmm.201201228","article-title":"miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity","volume":"4","author":"Allen","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0020","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/01.CIR.90.4.1935","article-title":"Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits","volume":"90","author":"Ameli","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0025","doi-asserted-by":"crossref","first-page":"19030","DOI":"10.3390\/molecules201019030","article-title":"miRNA stability in frozen plasma samples","volume":"20","author":"Balzano","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/ATVBAHA.112.300139","article-title":"Intercellular transport of microRNAs","volume":"33","author":"Boon","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/anie.201106455","article-title":"The tuberculosis drug streptomycin as a potential cancer therapeutic: Inhibition of miR-21 function by directly targeting its precursor","volume":"51","author":"Bose","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0050","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1161\/ATVBAHA.115.306506","article-title":"Therapeutic angiogenesis by ultrasound-mediated microRNA-126-3p delivery","volume":"35","author":"Cao","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0055","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3109\/10641963.2015.1036064","article-title":"Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension","volume":"37","author":"Cengiz","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0065","doi-asserted-by":"crossref","first-page":"121ra118","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/nmat4497","article-title":"Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment","author":"Conde","year":"2015","journal-title":"Nat Mater"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","article-title":"Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease?","volume":"110","author":"Creemers","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0080","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/cvr\/cvu162","article-title":"Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury","volume":"103","author":"Daniel","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0085","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3390\/ph6111361","article-title":"Nanoparticles as drug delivery systems in cancer medicine: Emphasis on RNAi-containing nanoliposomes","volume":"6","author":"Diaz","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0095","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.biomaterials.2014.05.009","article-title":"Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis","volume":"35","author":"Ding","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0100","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1073\/pnas.1322937111","article-title":"Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates","volume":"111","author":"Dong","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0105","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1038\/ncomms4065","article-title":"A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation","volume":"5","author":"Duivenvoorden","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0110","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: Progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0115","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nmeth1079","article-title":"MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells","volume":"4","author":"Ebert","year":"2007","journal-title":"Nat Methods"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Elmen","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0125","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/nar\/gkm1113","article-title":"Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver","volume":"36","author":"Elmen","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0135","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1126\/science.1121158","article-title":"The widespread impact of mammalian MicroRNAs on mRNA repression and evolution","volume":"310","author":"Farh","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCRESAHA.109.215566","article-title":"Circulating microRNAs in patients with coronary artery disease","volume":"107","author":"Fichtlscherer","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0145","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1172\/JCI109956","article-title":"A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family","volume":"66","author":"Franceschini","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0150","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.jacc.2013.10.056","article-title":"MicroRNAs and endothelial function: Many challenges and early hopes for clinical applications","volume":"63","author":"Frangogiannis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/ard.1994.4.201","article-title":"Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey","volume":"4","author":"Galbraith","year":"1994","journal-title":"Antisense Res Dev"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1476-511X-11-55","article-title":"Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease","volume":"11","author":"Gao","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0170","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): A second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0175","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058014","article-title":"Increased circulating miR-21 levels are associated with kidney fibrosis","volume":"8","author":"Glowacki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0185","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.15252\/emmm.201404046","article-title":"Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice","volume":"6","author":"Goedeke","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0190","doi-asserted-by":"crossref","first-page":"21816","DOI":"10.1074\/jbc.M111.327031","article-title":"Identifying functional microRNAs in macrophages with polarized phenotypes","volume":"287","author":"Graff","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.06.017","article-title":"MicroRNA targeting specificity in mammals: Determinants beyond seed pairing","volume":"27","author":"Grimson","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0200","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cell.2012.03.029","article-title":"A cardiac microRNA governs systemic energy homeostasis by regulation of MED13","volume":"149","author":"Grueter","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0205","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1002\/anie.200801555","article-title":"Small-molecule inhibitors of microrna miR-21 function","volume":"47","author":"Gumireddy","year":"2008","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003569","article-title":"Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs","volume":"9","author":"Hangauer","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0215","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/HYPERTENSIONAHA.111.187104","article-title":"MicroRNAs are involved in end-organ damage during hypertension","volume":"60","author":"Heggermont","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0220","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0225","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/oli.1.1997.7.503","article-title":"Inhibition of coagulation by a phosphorothioate oligonucleotide","volume":"7","author":"Henry","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0230","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/nat.2011.0332","article-title":"A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys","volume":"22","author":"Hildebrandt-Eriksen","year":"2012","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0240","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1073\/pnas.1016152108","article-title":"Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer","volume":"108","author":"Hsu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCRESAHA.111.244442","article-title":"Inhibition of miR-15 protects against cardiac ischemic injury","volume":"110","author":"Hullinger","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.12688\/f1000research.2-136.v1","article-title":"Clinical applications of microRNAs","volume":"2","author":"Hydbring","year":"2013","journal-title":"F1000Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0255","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2010.07.012","article-title":"MicroRNA-34a regulation of endothelial senescence","volume":"398","author":"Ito","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0260","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/anie.200805521","article-title":"Antagomirzymes: Oligonucleotide enzymes that specifically silence microRNA function","volume":"48","author":"Jadhav","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0265","first-page":"878","article-title":"HCV infection and miravirsen","volume":"369","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0270","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0275","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1039\/C4CC04514A","article-title":"Nonconventional chemical inhibitors of microRNA: Therapeutic scope","volume":"51","author":"Jayaraj","year":"2015","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0280","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCRESAHA.106.141986","article-title":"MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation","volume":"100","author":"Ji","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0285","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1002\/jps.23210","article-title":"Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins","volume":"101","author":"Jia","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0290","doi-asserted-by":"crossref","first-page":"15891","DOI":"10.3390\/ijms150915891","article-title":"Small engine, big power: MicroRNAs as regulators of cardiac diseases and regeneration","volume":"15","author":"Joladarashi","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kft278","article-title":"Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: Evidence of distinct pathways contributing to non-target mediated toxicity in mice","volume":"138","author":"Kakiuchi-Kiyota","year":"2014","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0300","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.172.11.6545","article-title":"Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3","volume":"172","author":"Kariko","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0305","doi-asserted-by":"crossref","first-page":"9449","DOI":"10.1021\/bi101185k","article-title":"\u201cLocked onto the target\u201d: Increasing the efficiency of antagomirzymes using locked nucleic acid modifications","volume":"49","author":"Kaur","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0310","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1021\/acsnano.5b02611","article-title":"Multifunctional nanoparticles facilitate molecular targeting and miRNA delivery to inhibit atherosclerosis in ApoE(\u2212\/\u2212) mice","volume":"9","author":"Kheirolomoom","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0315","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12975-015-0390-1","article-title":"Atherosclerosis-related circulating microRNAs as a predictor of stroke recurrence","volume":"6","author":"Kim","year":"2015","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050203","article-title":"Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development","volume":"5","author":"Kloosterman","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0325","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/mt.2014.73","article-title":"How to train your dragon: Targeted delivery of microRNA to cancer cells in vivo","volume":"22","author":"Kortylewski","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0330","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0335","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1161\/ATVBAHA.114.303425","article-title":"Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: Mechanosensitive athero-miRs","volume":"34","author":"Kumar","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0340","doi-asserted-by":"crossref","first-page":"8142","DOI":"10.1039\/C4TB00977K","article-title":"Inhibition of atherosclerosis-promoting microRNAs via targeted polyelectrolyte complex micelles","volume":"2","author":"Kuo","year":"2014","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0345","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/mt.2011.186","article-title":"Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein","volume":"19","author":"Kuwahara","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0350","first-page":"2045","article-title":"High density lipoprotein complexes as delivery vehicles for anticancer drugs","volume":"22","author":"Lacko","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0355","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000093268","article-title":"Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model","volume":"52","author":"Lacko","year":"2006","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0360","doi-asserted-by":"crossref","first-page":"7956","DOI":"10.1074\/jbc.M112.445429","article-title":"MicroRNA-92a negatively regulates toll-like receptor (TLR)-triggered inflammatory response in macrophages by targeting MKK4 kinase","volume":"288","author":"Lai","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0365","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0370","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","article-title":"Prediction of mammalian microRNA targets","volume":"115","author":"Lewis","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0375","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrd4359","article-title":"Therapeutic targeting of microRNAs: Current status and future challenges","volume":"13","author":"Li","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0380","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1083\/jcb.201208082","article-title":"Discovering the first microRNA-targeted drug","volume":"199","author":"Lindow","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0385","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/ATVBAHA.112.300068","article-title":"MicroRNAs in immune response and macrophage polarization","volume":"33","author":"Liu","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0390","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1016\/j.biomaterials.2014.05.081","article-title":"Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions","volume":"35","author":"Liu","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0395","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCRESAHA.114.302213","article-title":"Inhibition of microrna-92a prevents endothelial dysfunction and atherosclerosis in mice","volume":"114","author":"Loyer","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0400","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.tem.2009.05.007","article-title":"Meta-regulation: MicroRNA regulation of glucose and lipid metabolism","volume":"20","author":"Lynn","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0405","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/ATVBAHA.112.300639","article-title":"Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"33","author":"Marquart","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0410","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CAD.0b013e3282f1da86","article-title":"Evaluation of synthetic\/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel","volume":"19","author":"McConathy","year":"2008","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0415","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/nl1041947","article-title":"Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery","volume":"11","author":"McMahon","year":"2011","journal-title":"Nano Lett"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbalip.2016.01.011","article-title":"Lipoprotein carriers of microRNAs","author":"Michell","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0425","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.111.030932","article-title":"Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure","volume":"124","author":"Montgomery","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0430","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.15252\/emmm.201303604","article-title":"MicroRNA mimicry blocks pulmonary fibrosis","volume":"6","author":"Montgomery","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0435","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","article-title":"Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs","volume":"23","author":"Morrissey","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0440","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hep.27153","article-title":"Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia","volume":"60","author":"Ng","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140958","article-title":"MiR-486 and miR-92a identified in circulating HDL discriminate between stable and vulnerable coronary artery disease patients","volume":"10","author":"Niculescu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0450","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.786","article-title":"Silencing of microRNA families by seed-targeting tiny LNAs","volume":"43","author":"Obad","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0455","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0460","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jacc.2008.12.008","article-title":"Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes","volume":"53","author":"Patel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0465","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1021\/ja012288d","article-title":"Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids","volume":"124","author":"Petersen","year":"2002","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0470","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1073\/pnas.1208863110","article-title":"Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family","volume":"110","author":"Porrello","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0475","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2011.07.020","article-title":"miR-21, miR-210, miR-34a, and miR-146a\/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study","volume":"219","author":"Raitoharju","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0480","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.drudis.2008.03.014","article-title":"Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?","volume":"13","author":"Rayburn","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0485","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature10486","article-title":"Inhibition of miR-33a\/b in non-human primates raises plasma HDL and lowers VLDL triglycerides","volume":"478","author":"Rayner","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0490","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0495","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1126\/science.1189862","article-title":"MiR-33 contributes to the regulation of cholesterol homeostasis","volume":"328","author":"Rayner","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0500","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4155\/tde.12.41","article-title":"Drug delivery via lipoprotein-based carriers: Answering the challenges in systemic therapeutics","volume":"3","author":"Sabnis","year":"2012","journal-title":"Ther Deliv"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.tcm.2016.02.004","article-title":"MicroRNA: A new therapeutic strategy for cardiovascular diseases","author":"Samanta","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0510","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1073\/pnas.94.9.4262","article-title":"A general purpose RNA-cleaving DNA enzyme","volume":"94","author":"Santoro","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0515","first-page":"6","article-title":"Transcriptomic analysis of chronic hepatitis B and C and liver cancer reveals microRNA-mediated control of cholesterol synthesis programs","author":"Selitsky","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0520","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejcb.2010.06.005","article-title":"Upregulation of paxillin and focal adhesion signaling follows dystroglycan complex deletions and promotes a hypertensive state of differentiation","volume":"90","author":"Sen","year":"2011","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0525","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1593\/neo.101372","article-title":"Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles","volume":"13","author":"Shahzad","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.196","article-title":"Activation of the SIRT1\/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease","volume":"6","author":"Shan","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0535","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/nat.2012.0366","article-title":"Chemical modification study of antisense gapmers","volume":"22","author":"Stanton","year":"2012","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of microRNA function by antimiR oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0545","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/693234","article-title":"A biomimic reconstituted high density lipoprotein nanosystem for enhanced VEGF gene therapy of myocardial ischemia","author":"Sun","year":"2015","journal-title":"J Nanomater"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0550","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/cbic.201100789","article-title":"Antagonism of microRNA function in zebrafish embryos by using locked nucleic acid enzymes (LNAzymes)","volume":"13","author":"Suryawanshi","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0555","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0560","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/ncomms4292","article-title":"HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells","volume":"5","author":"Tabet","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0565","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nature10112","article-title":"MicroRNAs 103 and 107 regulate insulin sensitivity","volume":"474","author":"Trajkovski","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0570","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/cvr\/cvn156","article-title":"Role of microRNAs in vascular diseases, inflammation, and angiogenesis","volume":"79","author":"Urbich","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0575","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11906-012-0310-7","article-title":"Circulating miRNAs: Reflecting or affecting cardiovascular disease?","volume":"14","author":"van Empel","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0580","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/CIRCRESAHA.111.247916","article-title":"Developing microRNA therapeutics","volume":"110","author":"van Rooij","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0585","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1039\/c3cc00173c","article-title":"Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor","volume":"50","author":"Velagapudi","year":"2014","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0590","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.1452","article-title":"Sequence-based design of bioactive small molecules that target precursor microRNAs","volume":"10","author":"Velagapudi","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0595","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cbpa.2014.10.024","article-title":"Small molecule chemical probes of microRNA function","volume":"24","author":"Velagapudi","year":"2015","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0600","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MOL.0b013e328350a425","article-title":"Lipid-based carriers of microRNAs and intercellular communication","volume":"23","author":"Vickers","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0605","article-title":"HDL and cholesterol: Life after the divorce?","author":"Vickers","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0610","doi-asserted-by":"crossref","first-page":"14518","DOI":"10.1073\/pnas.1215767111","article-title":"MicroRNA-223 coordinates cholesterol homeostasis","volume":"111","author":"Vickers","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0615","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0620","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tibs.2014.10.009","article-title":"Mining diverse small RNA species in the deep transcriptome","volume":"40","author":"Vickers","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0625","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tcb.2014.11.004","article-title":"The biological functions of miRNAs: Lessons from in vivo studies","volume":"25","author":"Vidigal","year":"2015","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0630","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1021\/cb400668h","article-title":"Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules","volume":"9","author":"Vo","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0635","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/ATVBAHA.112.300741","article-title":"Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs","volume":"33","author":"Wagner","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0640","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/ATVBAHA.115.305597","article-title":"Local MicroRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis","volume":"35","author":"Wang","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0645","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3109\/10717544.2013.834418","article-title":"Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins","volume":"20","author":"Wang","year":"2013","journal-title":"Drug Deliv"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0650","article-title":"Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0655","first-page":"276540","article-title":"MicroRNAs in cerebral ischemia","volume":"2013","author":"Wang","year":"2013","journal-title":"Stroke Res Treat"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0660","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0665","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/smll.201001589","article-title":"Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles","volume":"7","author":"Yang","year":"2011","journal-title":"Small"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0670","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1021\/ja910275u","article-title":"Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma","volume":"132","author":"Young","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0675","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biomaterials.2012.09.058","article-title":"Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0680","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/mt.2014.25","article-title":"miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta\/Smad3 signaling","volume":"22","author":"Zhang","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.pharmthera.2016.09.001_bb0685","doi-asserted-by":"crossref","first-page":"184","DOI":"10.18433\/J3531X","article-title":"A simple method to extract whole apolipoproteins for the preparation of discoidal recombined high density lipoproteins as bionic nanocarriers for drug delivery","volume":"18","author":"Zhang","year":"2015","journal-title":"J Pharm Pharm Sci"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T10:21:44Z","timestamp":1568370104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816301577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":137,"alternative-id":["S0163725816301577"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.09.001","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDL and microRNA therapeutics in cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}